Clinical Trials Logo

Filter by:
NCT ID: NCT05387668 Withdrawn - Healthy Volunteers Clinical Trials

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Start date: February 17, 2022
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the influence of ethnic factors on the safety, tolerability, and pharmacokinetics (PK) of BGB-23339 after multiple dosing under fasting condition in healthy Japanese and Caucasian participants.

NCT ID: NCT05387642 Withdrawn - Essential Tremor Clinical Trials

A Clinical Trial of PRAX-114 in Participants With Essential Tremor

Start date: April 5, 2022
Phase: Phase 2
Study type: Interventional

This is a 2-part clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of PRAX-114 in participants with essential tremor (ET). Part A is a randomized, double-blind, placebo-controlled, three-period, three-sequence, crossover design where participants will receive a single dose of 10 mg PRAX-114, 20 mg PRAX-114, and matching placebo. Part B is an open-label design where participants from Part A, after washout and confirmation of eligibility may elect to participate in Part B where all participants will receive 10 mg once every morning (QAM) for the first 14 days. Based on investigator judgement of the safety and tolerability, the dose for Days 15 to 28 could be increased to 20 mg QAM.

NCT ID: NCT05386862 Withdrawn - Clinical trials for Post Traumatic Stress Disorder

Warrior CARE: Naturalistic Observation and Harm Reduction

NOC
Start date: July 13, 2022
Phase: N/A
Study type: Interventional

This study is looking at therapeutic potential of reducing Tetrahydrocannabinol (THC) levels in regular cannabis smokers using contingency management (CM) intervention in a U.S. veteran population with post-traumatic stress disorder (PTSD).

NCT ID: NCT05381974 Withdrawn - Clinical trials for Treatment-Resistant Major Depressive Disorder

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Start date: September 15, 2022
Phase: Phase 2
Study type: Interventional

This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.

NCT ID: NCT05379907 Withdrawn - Pancreatic Cancer Clinical Trials

Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

Start date: August 23, 2022
Phase:
Study type: Observational

The purpose of this study is to collect information about treatment recommendations based on ctDNA testing and whether treatment changes based on ctDNA information result in better outcomes for patients with pancreatic cancer.

NCT ID: NCT05379439 Withdrawn - Clinical trials for Chronic Respiratory Failure

Family Connections

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study seeks to evaluate a Structured Family Deliberation that will serve as the primary intervention in a multicenter controlled trial involving families considering tracheostomy and home ventilation for the child. In this study, the investigators will evaluate the feasibility, usefulness, face validity, and preliminary impact of this approach on preparedness for decision making among participants.

NCT ID: NCT05375825 Withdrawn - Clinical trials for Epithelial Tumors, Malignant

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Start date: January 31, 2024
Phase: Phase 1
Study type: Interventional

Background: Cancers that spread into the thin tissue lining your lungs (pleura) cause serious illness. They often recur when removed. These tumors include malignant pleural mesothelioma (MPM), caused by exposure to asbestos and related fibers. Malignant pleural effusions (MPEs) are caused when cancers in other parts of the body spread to the lungs and pleura. Many people diagnosed with pleural tumors survive less than a year. Objective: To test the safety of a study drug (LMB-100) in people. LMB-100 may help stop pleural tumors from recurring after surgery. Eligibility: People aged 18 years or older diagnosed with MPM or related cancer that has spread into the pleura. Design: Participants will undergo screening. They will have a physical exam with blood and urine tests. They will have CT scans. They will have tests that measure the how their heart and lungs function. They will provide a sample of tumor tissue to determine if their tumor expresses a protein called mesothelin. Participants will undergo standard surgery to maximally remove the plural tumors. Then they will have LMB-100 pumped into their chest. The liquid will rinse the chest wall, diaphragm, heart sac, and surface of the lungs for 90 minutes. Then the liquid will be drained and the surgical incisions closed. The participants will be under anesthesia during this procedure. Participants will remain in the intensive care unit for a least 48 hours. They will remain in the hospital for up to a week or more until recovered enough to be safely discharged. Participants will return for regular follow-up visits for 2 years.

NCT ID: NCT05373381 Withdrawn - Glioma Clinical Trials

The KetoGlioma (Ketogenic Glioma) Study

Start date: May 18, 2022
Phase: N/A
Study type: Interventional

This research is being conducted to see if patients diagnosed with high grade gliomas can adhere to the supplemented High-Fat Low-Carbohydrate (sHFLC) + KetoPhyt diet, and to see how this diet might affect cancer cells in the bloodstream. This diet is experimental and is not routinely prescribed for patients with high-grade gliomas. The results of this study may be used to support larger studies investigating possible anti-tumor affects of the sHFLC + KetoPhyt diet.

NCT ID: NCT05372783 Withdrawn - COVID-19 Clinical Trials

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

Start date: April 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal STI-9199 in adults and adolescents who are COVID-19 positive with mild to moderate symptoms.

NCT ID: NCT05371951 Withdrawn - Clinical trials for Erectile Dysfunction

Effect of Erchonia Laser on Erectile Dysfunction

Start date: October 5, 2021
Phase: N/A
Study type: Interventional

This study is to see if applying low-level laser light can provide improvement in erectile dysfunction